We are live on ! Find out more
UNCY icon

Unicycive Therapeutics
UNCY

23 hedge funds and large institutions have $31.6M invested in Unicycive Therapeutics in 2024 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 8 increasing their positions, 1 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

700% more repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 1

179% more capital invested

Capital invested by funds: $11.3M → $31.6M (+$20.3M)

44% more funds holding

Funds holding: 16 → 23 (+7)

2.36% more ownership

Funds ownership: 3.75% → 6.11% (+2.4%)

Holders
23
Holders Change
+7
Holders Change %
+43.75%
% of All Funds
0.33%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
8
Reduced
1
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
LGM
Logos Global Management
California
+$4.21M
2
RA
Rosalind Advisors
Ontario, Canada
+$2.28M
3
BI
BVF Inc
California
+$1.81M
4
MIM
Monashee Investment Management
Massachusetts
+$1.21M
5
Vanguard Group
Vanguard Group
Pennsylvania
+$273K

Top Sellers

Rank Fund Capital Flow
1
NCM
Nantahala Capital Management
Connecticut
-$124K
Name Holding Trade Value Shares
Change 		Change in
Stake
NCM
1
Nantahala Capital Management
Connecticut
$8.64M -$124K -10,259 -3%
BI
2
BVF Inc
California
$4.98M +$1.81M +149,346 +71%
RCM
3
RA Capital Management
Massachusetts
$4.79M – – –
VC
4
Vivo Capital
California
$4.79M – – –
LGM
5
Logos Global Management
California
$3.01M +$4.21M +346,993 New
RA
6
Rosalind Advisors
Ontario, Canada
$2.59M +$2.28M +187,965 New
MIM
7
Monashee Investment Management
Massachusetts
$1.38M +$1.21M +100,000 New
Vanguard Group
8
Vanguard Group
Pennsylvania
$469K +$273K +22,480 +195%
Geode Capital Management
9
Geode Capital Management
Massachusetts
$349K +$102K +8,406 +50%
Goldman Sachs
10
Goldman Sachs
New York
$129K – – –
Renaissance Technologies
11
Renaissance Technologies
New York
$128K +$71.3K +5,877 +172%
Citadel Advisors
12
Citadel Advisors
Florida
$95.8K +$41.2K +3,398 +96%
State Street
13
State Street
Massachusetts
$48.4K – – –
VF
14
Virtu Financial
New York
$36K +$31.6K +2,608 New
Northern Trust
15
Northern Trust
Illinois
$33.1K +$29.1K +2,400 New
GSC
16
Ground Swell Capital
South Carolina
$26.4K +$23.2K +1,912 New
CAPTRUST Financial Advisors
17
CAPTRUST Financial Advisors
North Carolina
$25.9K – – –
TCM
18
Tandem Capital Management
New Jersey
$21.4K – – –
IWC
19
Integrated Wealth Concepts
Massachusetts
$13.8K – – –
TRCT
20
Tower Research Capital (TRC)
New York
$10.6K +$1.11K +92 +14%
UBS Group
21
UBS Group
Switzerland
$6.05K +$5.1K +421 +2,339%
Wells Fargo
22
Wells Fargo
California
$270 +$12 +1 +5%
JP Morgan Chase
23
JP Morgan Chase
New York
$65 +$61 +5 New

UNCY Hedge Fund Activity: Q1 2024 in Review

23 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Unicycive Therapeutics (UNCY) for Q1 2024, worth a combined $31.6M — up 179% from $11.3M a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new UNCY positions and 0 closed out — a net gain of 7 holders — while 8 added to existing stakes and 1 trimmed.

The largest buyer was Logos Global Management, opening a new position worth an estimated $4.21M. The largest seller was Nantahala Capital Management, cutting an estimated $124K.

  • 23 institutional investors held Unicycive Therapeutics (UNCY) as of Q1 2024, up from 16 in Q4 2023.
  • Funds reported $31.6M of Unicycive Therapeutics stock for Q1 2024, up 179% quarter-over-quarter.
  • 7 funds opened new Unicycive Therapeutics positions in Q1 2024 and 0 closed out, a net change of +7 holders.
  • The largest Unicycive Therapeutics buyer in Q1 2024 was Logos Global Management, an estimated $4.21M added.
  • The largest Unicycive Therapeutics seller in Q1 2024 was Nantahala Capital Management, an estimated $124K sold.

Based on aggregated 13F filings for Q1 2024.